A phase 1b study of the combination of MLN0128 (dual TORC1/2 inhibitor) and MLN8237 (Aurora A inhibitor, alisertib) in patients with advanced solid tumors

被引：1
|
作者：
Davis, S. Lindsey [1 ]
Lam, Elaine T. [1 ]
Corr, Bradley R. [1 ]
O'Bryant, Cindy L. [1 ]
Glode, Ashley [1 ]
Adler, Nichole [1 ]
Pitts, Todd M. [1 ]
Tentler, John J. [1 ]
Capasso, Anna [1 ]
Dailey, Kyrie [1 ]
Serkova, Natalie J. [1 ]
Weekes, Colin D. [2 ]
Gustafson, Daniel L. [3 ]
Lieu, Christopher H. [1 ]
Messersmith, Wells A. [1 ]
Leong, Stephen [1 ]
Eckhardt, S. Gail [4 ]
Diamond, Jennifer R. [1 ]
机构：
[1] Univ Colorado, Denver, CO 80202 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Colorado State Univ, Ft Collins, CO 80523 USA
[4] Univ Texas Austin, Austin, TX 78712 USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2018年 / 17卷 / 01期
关键词：
D O I：
10.1158/1535-7163.TARG-17-A083
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A083
引用
收藏
页数：2
相关论文
共 50 条
  • [31] EFFECTS OF TORC1/2 INHIBITOR MLN0128 ALONE AND IN COMBINATION WITH MEK INHIBITION IN BRAF MUTATED GLIOMA MODELS IN VITRO AND IN VIVO
    Liu, Kevin X.
    Mueller, Sabine
    Dik, Rogier
    Yang, Xiaodong
    DuBois, Steven
    Waanders, Angela J.
    Resnick, Adam C.
    Weiss, William A.
    Haas-Kogan, Daphne
    NEURO-ONCOLOGY, 2017, 19 : 85 - 86
  • [32] Biotransformation Pathways and Metabolite Profiles of Oral [14C]Alisertib (MLN8237), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
    Pusalkar, Sandeepraj
    Zhou, Xiaofei
    Li, Yuexian
    Cohen, Lawrence
    Yang, Jun Johnny
    Balani, Suresh K.
    Xia, Cindy
    Shyu, Wen Chyi
    Lu, Chuang
    Venkatakrishnan, Karthik
    Chowdhury, Swapan K.
    DRUG METABOLISM AND DISPOSITION, 2020, 48 (03) : 217 - 229
  • [33] Development of a phase 2 study of the aurora kinase-A inhibitor alisertib (MLN8237) in pretreated patients (pts) with urothelial cancer (UC).
    Necchi, Andrea
    Mariani, Luigi
    Giannatempo, Patrizia
    Raggi, Daniele
    Fare, Elena
    Marchlano, Alfonso
    Crippa, Flavlo
    Togllardi, Elena
    Daldone, Maria Grazla
    Gianni, Alessandro M.
    Salvioni, Roberto
    De Braud, Filippo G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] Integrated Safety Analysis of Single-Agent MLN8237 (alisertib), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies and Solid Tumors
    Benaim, Ely
    Zhou, Xiaofei
    Liu, Hua
    Leonard, E. Jane
    Freedland, Eric
    Niculescu, Liviu
    BLOOD, 2012, 120 (21)
  • [35] STM-01: Phase I EFFTox study of aurora A kinase inhibitor alisertib (MLN8237) given in combination with selective VEGFR inhibitor pazopanib for therapy of solid tumors.
    Dudek, Arkadiusz Z.
    Unal, Imran
    Xie, Hui
    Feldman, Lawrence Eric
    Venepalli, Neeta K.
    Danciu, Oana Cristina
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] STM-01: Phase I EffTox study of aurora A kinase inhibitor alisertib (MLN8237) given in combination with selective VEGFR inhibitor pazopanib for therapy of solid tumors.
    Shah, Hirai A.
    Christian, Sonia
    Ahmed, Bilawal
    Chowdhery, Rozina A.
    Venepalli, Neeta K.
    Danciu, Oana Cristina
    Dudek, Arkadiusz Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] Effects of alisertib (MLN8237), an investigational Aurora A kinase inhibitor (AAKi), on the QTc interval in patients (pts) with advanced malignancies
    Zhou, X.
    Nemunaitis, J.
    Pant, S.
    Bauer, T. M.
    Patel, M.
    Sarantopoulos, J.
    Lockhart, A. C.
    Goodman, D.
    Zhang, B.
    Ullmann, C. Dansky
    Mould, D. R.
    Venkatakrishnan, K.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S76 - S77
  • [38] Mass balance, routes of excretion, and pharmacokinetics of investigational oral [14C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors
    Xiaofei Zhou
    Sandeepraj Pusalkar
    Swapan K. Chowdhury
    Shawn Searle
    Yuexian Li
    Claudio Dansky Ullmann
    Karthik Venkatakrishnan
    Investigational New Drugs, 2019, 37 : 666 - 673
  • [39] Mass balance, routes of excretion, and pharmacokinetics of investigational oral [14C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors
    Zhou, Xiaofei
    Pusalkar, Sandeepraj
    Chowdhury, Swapan K.
    Searle, Shawn
    Li, Yuexian
    Ullmann, Claudio Dansky
    Venkatakrishnan, Karthik
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (04) : 666 - 673
  • [40] Effects of rifampin, a strong metabolic enzyme inducer, on the pharmacokinetics (PK) of alisertib (MLN8237), an investigational Aurora A kinase inhibitor (AAKi), in patients with advanced solid tumors or lymphomas
    Zhou, X.
    Pant, S.
    Sarantopoulos, J.
    Patel, M.
    Nemunaitis, J.
    Lockhart, A. C.
    Zhang, B.
    Bargfrede, M.
    Muehler, A.
    Venkatakrishnan, K.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S76 - S76
12345